IBDEI0Y9 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16912,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,16913,0)
 ;;=V10.82^^92^943^40
 ;;^UTILITY(U,$J,358.3,16913,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16913,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,16913,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,16913,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,16914,0)
 ;;=V10.62^^92^943^43
 ;;^UTILITY(U,$J,358.3,16914,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16914,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,16914,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,16914,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,16915,0)
 ;;=V10.63^^92^943^41
 ;;^UTILITY(U,$J,358.3,16915,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16915,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,16915,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,16915,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,16916,0)
 ;;=V11.2^^92^943^32
 ;;^UTILITY(U,$J,358.3,16916,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16916,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,16916,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,16916,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,16917,0)
 ;;=V15.81^^92^943^60
 ;;^UTILITY(U,$J,358.3,16917,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16917,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,16917,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,16917,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,16918,0)
 ;;=V10.43^^92^943^44
 ;;^UTILITY(U,$J,358.3,16918,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16918,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,16918,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,16918,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,16919,0)
 ;;=V12.71^^92^943^45
 ;;^UTILITY(U,$J,358.3,16919,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16919,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,16919,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,16919,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,16920,0)
 ;;=V10.46^^92^943^48
 ;;^UTILITY(U,$J,358.3,16920,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16920,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,16920,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,16920,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,16921,0)
 ;;=V11.0^^92^943^50
 ;;^UTILITY(U,$J,358.3,16921,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16921,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,16921,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,16921,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,16922,0)
 ;;=V10.83^^92^943^51
 ;;^UTILITY(U,$J,358.3,16922,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16922,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,16922,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,16922,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,16923,0)
 ;;=V15.1^^92^943^53
 ;;^UTILITY(U,$J,358.3,16923,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16923,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,16923,1,5,0)
 ;;=5^Hx of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,16923,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,16924,0)
 ;;=V15.82^^92^943^57
 ;;^UTILITY(U,$J,358.3,16924,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16924,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,16924,1,5,0)
 ;;=5^Hx of Tobacco Use (not current)
 ;;^UTILITY(U,$J,358.3,16924,2)
 ;;=Hx of Tobacco Use (not current)^303405
 ;;^UTILITY(U,$J,358.3,16925,0)
 ;;=V12.01^^92^943^54
 ;;^UTILITY(U,$J,358.3,16925,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16925,1,4,0)
 ;;=4^V12.01
